A new drug against tuberculosis (TB) will be developed based on the inhibition of the 1-deoxy-D-xylulose 5-phosphate (DOXP) pathway. The DOXP pathway supplies M. tuberculosis with essential isoprenoids. In mammals, the DOXP pathway is absent and isoprenoids are synthesised by the evaluate pathway. Therefore, inhibitors of the DOXP pathway are non-toxic for the human host. Inhibitors of DOXPreductoisomerase (Dry), key enzymes of the DOXP pathway, are to be developed as potential anti-TB drugs. In addition, the crystal structure of the Gape enzyme will be solved to provide the base for future drug development.
Funding SchemeCSC - Cost-sharing contracts
2288 GJ Rijswijk Zh
E1 4NS London